Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms

Autor: Bellati, Filippo, Napoletano, Chiara, Gasparri, Marialuisa, Ruscito, Ilary, Marchetti, Claudia, Claudia, Marchetti, Sandro, Pignata, Tomao, Federica, Panici, P. B., BENEDETTI PANICI, Pierluigi, Nuti, Marianna
Rok vydání: 2012
Předmět:
Vascular Endothelial Growth Factor A
Oncology
medicine.medical_specialty
Bevacizumab
Genital Neoplasms
Female
Angiogenesis
Angiogenesis Inhibitors
Disease
Pharmacology
gynecologic oncology
Antibodies
Monoclonal
Humanized
Target therapy
Drug Administration Schedule
chemistry.chemical_compound
Ovarian cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Chemotherapy
Clinical significance
Adverse effect
Gynaecological cancer
Clinical Trials as Topic
Settore MED/06 - ONCOLOGIA MEDICA
Neovascularization
Pathologic
business.industry
Hematology
gynaecological cancer
vegf
ovarian cancer
target therapy
cervical cancer
bevacizumab
angiogenesis
chemotherapy
medicine.disease
VEGF
Tumor Burden
Clinical trial
Vascular endothelial growth factor
Settore MED/40 - GINECOLOGIA E OSTETRICIA
chemistry
Cervical cancer
Female
business
medicine.drug
Zdroj: Critical Reviews in Oncology/Hematology. 83:35-46
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2011.09.006
Popis: In the last fifty years the combining of different drugs has progressively improved response and survival rates in gynaecological malignancies. Results are, however, far from being satisfactory. Treatments used in cases of advanced or recurrent disease offer limited results in terms of long-term responses and the urgent need for new drugs has prompted researchers to investigate and propose new therapeutic modalities. One of the most important avenues that are being explored is represented by monoclonal antibodies (MoAb) directed against Vascular Endothelial Growth Factor (VEGF). Several antibodies against this target are now available and Bevacizumab appears to be one of the most promising agents. VEGF has been confirmed as an important therapeutic target in several clinical trials and in multiple disease settings, including gynaecological cancers, for its biological and clinical significance in tumour angiogenesis. The binding and blocking of VEGF growth factor is the basis of tumour growth inhibition, since angiogenesis is essential in the process of tumour growth and progression. Several clinical trials have utilized this agent successfully, either alone or in combination with other drugs. Despite initial concerns, adverse reactions have not been significant with side effects being more tolerable than those associated to conventional chemotherapy. Furthermore, the limited toxicity profile of this, as well as other target therapies, allows it to be combined with cytotoxic drugs without the requirement for a significant dose reduction of the latter. This review outlines the rationale for studying this anti-angiogenetic compound, summarizing the existing and emerging clinical evidence related to the use of Bevacizumab in the treatment of gynaecological malignancies, focusing on its potential benefits and adverse effects.
Databáze: OpenAIRE
Externí odkaz: